Skip to main content
. 2020 Jun 5;21(11):4050. doi: 10.3390/ijms21114050

Figure 1.

Figure 1

Molecular structures and antiviral abilities of a series of afatinib-derivative tyrosine kinase inhibitor (TKI) compounds. (A) Schematic structures of afatinib and compounds 10b, L1, and L3. (B) HEK-293 cells were treated with a solvent or with different concentrations of afatinib and compounds 10b, L1, and L3 for 36 h. The WST-1 assay was used to measure cell viability. A percentage was obtained by comparison with the solvent control, set at 100%. (C,D) HEK-293 cells infected with dengue virus (DENV)-2 (multiplicity of infection (MOI) = 1) and treated with afatinib (C) or with compounds 10b, L1, and L3 (D) at 10 and 20 μM. After 36 h, a Western blot analysis of viral protein levels in the cell lysates was performed, and the ratio of the viral NS3 protein level to the level of actin was adjusted to that of the solvent control. Data are the mean ± SD of three independent experiments. * p < 0.05, ** p < 0.01 according to a two-tailed Student’s t-test.